Agios Pharmaceuticals (AGIO) Cash from Investing Activities (2012 - 2026)

Agios Pharmaceuticals' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at $141.3 million for Q1 2026.

• Quarterly Cash from Investing Activities rose 25.51% year-over-year to $141.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $405.9 million (up 15.49% YoY) and the FY2025 annual result came in at $377.2 million, up 3.78% from the prior year.
• Cash from Investing Activities was $141.3 million for Q1 2026 at Agios Pharmaceuticals, up from $90.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $250.8 million in Q3 2024 and bottomed at -$49.2 million in Q4 2024.
• A 5-year average of $80.3 million and a median of $83.0 million in 2022 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 537.49% in 2024, while the deepest fall reached 151.47% in 2024.
• Agios Pharmaceuticals' Cash from Investing Activities stood at $83.0 million in 2022, then increased by 15.14% to $95.5 million in 2023, then tumbled by 151.47% to -$49.2 million in 2024, then jumped by 283.24% to $90.1 million in 2025, then surged by 56.88% to $141.3 million in 2026.
• Business Quant data shows AGIO's Cash from Investing Activities at $141.3 million in Q1 2026, $90.1 million in Q4 2025, and $95.6 million in Q3 2025.